

RESEARCH
Tata Consultancy Services | Target: Rs 3,710 | +19% | BUY

Strongest Q3 in nine years – growth and margins outperform

Media & Entertainment

Strong content slate to boost multiplex occupancy in FY22

SUMMARY
Tata Consultancy Services

TCS's QoQ dollar revenue growth of 5.1% beat street estimates (~3.1%) in a seasonally weak quarter. Growth was broad-based across verticals and geographies. Adj. EBIT margin stood at 26.6%, up 40bps QoQ despite salary hikes. TCV was strong at US\$ 6.8bn. We raise our target P/E to 27.4x from 24.2x backed by strong demand growth and stable margins. On rollover, we have a revised Dec'22 TP of Rs 3,710 (Rs 3,180 earlier). Being the industry leader, TCS will be the prime beneficiary of vendor consolidation. BUY.

[Click here for the full report.](#)

Media & Entertainment

We hosted Amit Sharma, MD – Miraj Entertainment, on a call with select investors. Key takeaways: 1) Footfalls gained some traction after release of 'Tenet' and 'Wonder Woman 1984' in Dec'20, 2) FY22 content slate appears to be strong with at least 25 upcoming movies where management sees blockbuster potential (collection of Rs 1bn+), 3) management expects to revert to EBITDA breakeven in Apr'21, and reach pre-Covid occupancy levels by Jul'21, and 4) rentals for new screens have declined 30-35% post Covid, which augurs well for multiplexes.

[Click here for the full report.](#)

TOP PICKS
LARGE-CAP IDEAS

Company	Rating	Target
Cipla	Buy	900
GAIL	Buy	155
Petronet LNG	Buy	330
TCS	Buy	3,710
Tech Mahindra	Buy	1,040

MID-CAP IDEAS

Company	Rating	Target
Alkem Labs	Buy	3,600
Greenply Industries	Buy	150
Laurus Labs	Buy	410
Transport Corp	Buy	300
Mahanagar Gas	Sell	750

Source: BOBCAPS Research

DAILY MACRO INDICATORS

Indicator	Current	2D (%)	1M (%)	12M (%)
US 10Y yield (%)	1.08	4bps	16bps	(78bps)
India 10Y yield (%)	5.86	0bps	2bps	(67bps)
USD/INR	73.32	(0.3)	0.8	(3.0)
Brent Crude (US\$/bbl)	54.38	0.1	11.5	(16.8)
Dow	31,041	0.7	3.2	7.2
Shanghai	3,576	0.7	4.7	15.6
Sensex	48,093	(0.2)	5.9	16.0
India FII (US\$ mn)	6 Jan	MTD	CYTD21	FYTD
FII-D	(9.0)	151.7	151.7	(3,941.9)
FII-E	(47.2)	465.8	465.8	30,441.6

Source: Bank of Baroda Economics Research

BOBCAPS Research

research@bobcaps.in



BUY

TP: Rs 3,710 | ▲ 19%

**TATA CONSULTANCY
SERVICES**

| IT Services

| 08 January 2021

Strongest Q3 in nine years – growth and margins outperform

TCS's QoQ dollar revenue growth of 5.1% beat street estimates (~3.1%) in a seasonally weak quarter. Growth was broad-based across verticals and geographies. Adj. EBIT margin stood at 26.6%, up 40bps QoQ despite salary hikes. TCV was strong at US\$ 6.8bn. We raise our target P/E to 27.4x from 24.2x backed by strong demand growth and stable margins. On rollover, we have a revised Dec'22 TP of Rs 3,710 (Rs 3,180 earlier). Being the industry leader, TCS will be the prime beneficiary of vendor consolidation. **BUY.**

Ruchi Burde | Seema Nayak

research@bobcaps.in

Stellar Q3 performance: TCS reported QoQ revenue growth of 4.1% CC/ 5.1% USD, beating our optimistic estimates of 2.6% CC/3% USD and setting the tone for a strong Q3 for Indian IT despite seasonality. At 2.1%, YoY growth was positive for the first time since pandemic onset. Demand is robust as indicated by TCV of US\$ 6.8bn (excluding Postbank acquisition), up 13% YoY. Geographically, India grew the highest at 18.1% QoQ CC. North America was strong at 3.3% CC, followed by Europe at 2.5%. Vertical-wise, life sciences/ manufacturing posted stellar growth of 5.2%/7.1% CC. BFSI/retail-CPG increased 2%/3.1% QoQ. The strong all-round showing indicates the beginning of a multi-year demand growth cycle wherein TCS will be the prime beneficiary.

Margins surprise: Adj. EBIT margin at 26.6% expanded 40bps QoQ (est. 24.7%), entering TCS's target band of 26-28% and recovering from a trough of 23.6% in Q1. Management expects to maintain margins, aided by accelerated growth.

Strong BFSI TCV growth: BFSI is gaining momentum with TCV at an all-time high of US\$ 2.6bn (+44% YoY), excluding Postbank. Growth was aided by closure of the Prudential deal in December. TCS is beginning to invest more in Europe as it sees opportunity there. However, UK banking remains stressed.

Ticker/Price	TCS IN/Rs 3,121
Market cap	US\$ 159.9bn
Shares o/s	3,753mn
3M ADV	US\$ 132.8mn
52wk high/low	Rs 3,128/Rs 1,506
Promoter/FPI/DII	72%/17%/11%

Source: NSE

STOCK PERFORMANCE

Source: NSE

KEY FINANCIALS

Y/E 31 Mar	FY19A	FY20A	FY21E	FY22E	FY23E
Total revenue (Rs mn)	1,464,630	1,569,490	1,662,306	2,106,950	2,489,786
EBITDA (Rs mn)	395,050	421,100	467,862	603,187	702,831
Adj. net profit (Rs mn)	315,240	323,400	337,873	444,595	518,335
Adj. EPS (Rs)	84.0	86.2	91.3	120.2	140.1
Adj. EPS growth (%)	25.3	2.6	6.0	31.6	16.6
Adj. ROAE (%)	35.5	37.0	37.7	43.6	42.1
Adj. P/E (x)	37.2	36.2	34.2	26.0	22.3
EV/EBITDA (x)	29.5	27.7	24.9	19.4	16.6

Source: Company, BOBCAPS Research



MEDIA & ENTERTAINMENT

08 January 2021

Strong content slate to boost multiplex occupancy in FY22

We hosted Amit Sharma, MD – Miraj Entertainment (Miraj), on a call with select investors. Following are the key takeaways:

Sayan Das Sharma
 research@bobcaps.in

- Though cinema screens reopened in mid-October, footfalls were negligible till end-November due to weak content. Since the release of 'Tenet' and 'Wonder Woman 1984' in December, footfalls have gained traction. South Indian circuits have done relatively better due to good regional content.
- Miraj believes a lack of good content rather than virus fears is the key reason behind muted footfalls. Big-ticket films are unlikely to opt for theatrical release till 100% occupancy is restored in cinema halls.
- Management expects to revert to EBITDA breakeven in Apr'21. A strong movie slate in FY22 – at least 25 upcoming movies where management sees blockbuster potential (collection of Rs 1bn+) – should take occupancy back to pre-Covid levels by Jul'21.
- Advertising revenue may take longer than other revenue streams (exhibition, F&B) to normalise. If pre-Covid occupancy is achieved in Q2FY22, ad revenue should gather traction from Q3FY22 onwards.
- Miraj has entered into rent-sharing agreements with some mall developers. The revenue share varies depending on attractiveness of the property.
- The company has also taken several new initiatives to save costs such as installation of QR codes for F&B orders and manpower rationalisation. Management expects some of these initiatives to continue post FY21 as well.
- About 1,000-1,500 single-screen properties are estimated to have closed down following the pandemic, mainly in South India. Hence, some footfalls are likely to be diverted to multiplexes in these regions.
- The multiplex industry may see only 150-200 new screens in FY22 due to tight liquidity with exhibitors. Screen additions from FY23 on should total 300-350 a year, but are contingent upon the pace of mall development.
- Pre-Covid, Miraj had 25 screens in the fit-out stage which are likely to be completed in FY21. Rentals for new properties have declined 30-35%, which is a major positive for the industry.

RECOMMENDATION SNAPSHOT

Ticker	Target	Rating
PVRL IN	1,160	REDUCE
INOL IN	315	BUY

Target in Rupees



Disclaimer

Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

ADD – Expected return from >+5% to +15%

REDUCE – Expected return from -5% to +5%

SELL – Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

Rating distribution

As of 31 December 2020, out of 88 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 43 have BUY ratings, 14 have ADD ratings, 6 are rated REDUCE and 25 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.